Entrada Therapeutics, Inc. (TRDA) Market Cap & Valuation Ratios
Entrada Therapeutics, Inc. (TRDA) has a market cap of $171.7M and a price-to-sales ratio of 36.6, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TRDAEntrada Therapeutics, Inc.Follow TRDA — free
—
Price chart with a free account
- Market cap
- 171.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Peers
biotechnology · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| TRDA | 0.2 | — | 15.5 | — | — | -94% | — | -80% |
| ALEC | 0.2 | — | 3.0 | — | — | -83% | — | — |
| NAGE | 0.2 | 13.5 | 1.0 | 11.3 | 3.0% | +11% | 8% | 102% |
| ADCT | 0.2 | — | 1.0 | — | — | +3% | -125% | — |
| KRRO | 0.2 | — | 25.8 | — | — | -62% | — | -138% |
| SION | 0.2 | — | — | — | — | — | — | -44% |
| CHRS | 0.2 | — | 1.7 | — | — | +61% | -312% | — |
| MDWD | 0.2 | — | 12.6 | — | — | -40% | -268% | -126% |
| UPB | 0.2 | — | — | — | — | +16% | — | -61% |
| RNA | 0.1 | — | — | — | — | — | — | — |
| CDXS | 0.1 | — | 1.6 | — | -8.7% | +36% | -36% | -48% |
| Median of these 10 | 13.5 | 1.7 | 11.3 | -2.9% | +7% | -125% | -55% |
; EV/Sales 15.5 vs. 1.7.
Growth vs. price
each dot a company · hover or tap for valuesEntrada Therapeutics, Inc. — questions
- What is Entrada Therapeutics, Inc.'s market cap?
- $171.7M.
- What is Entrada Therapeutics, Inc.'s price-to-sales ratio?
- 36.6.
Every figure on this page comes from Entrada Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.